Improvements in Diabetic Neuropathy with Topical Human Mesenchymal Stem Cell Conditioned Media
Pilot study of a topical mesenchymal stem cell media–conditioned cream (Neurocream) applied twice daily to the soles of the feet after brief micro-needling in type-2 diabetic and non-diabetic patients with progressive neuropathy. T2D participants reported approximately a 50% average reduction across foot pain, tingling, and swelling at 30 days; non-T2D participants reported a 57% reduction in swelling and 40% reduction in foot pain. All participants reported improved sleep.
Pilot study of a topical mesenchymal stem cell media–conditioned cream (Neurocream) applied twice daily to the soles of the feet after brief micro-needling in type-2 diabetic and non-diabetic patients with progressive neuropathy. T2D participants reported approximately a 50% average reduction across foot pain, tingling, and swelling at 30 days; non-T2D participants reported a 57% reduction in swelling and 40% reduction in foot pain. All participants reported improved sleep.
Pilot clinical trial (n=12) evaluating a topical stem cell–conditioned skin cream applied over eight weeks to address age-related skin concerns including tone, texture, brightness, and fine lines. Discussion covers the biology of skin senescence, paracrine signaling by MSCs, and the growth-factor and cytokine cargo underlying observed improvements in skin aesthetics.
Single-center 30-day clinical study (n=15, ages 18–43) of a topical acne product combining stem cell–conditioned media with salicylic acid. Analysis showed a statistically significant improvement in overall acne lesion appearance from baseline at day 30 (p=0.004) and strong participant-reported improvements in skin texture, with a favorable safety profile.